by Michael Nevradakis, Ph.D., Childrens Health Defense:
During three days of meetings last week, advisers to the Centers for Disease Control and Prevention last week voted unanimously in favor of recommending Pfizer’s new 20-valent pneumococcal conjugate vaccine — currently administered only to adults — as an “option” for children.
Advisers to the Centers for Disease Control and Prevention (CDC) last week recommended newly approved vaccines for respiratory syncytial virus (RSV) — despite concerns about the efficacy and safety of the new vaccines, potentially harmful interactions with the flu and COVID-19 vaccines and the unspecified cost for the vaccines.
TRUTH LIVES on at https://sgtreport.tv/
In a three-day meeting that ended Friday, the CDC’s Advisory Committee on Immunization Practices (ACIP) also:
- Recommended a new pneumococcal conjugate vaccine as an “option” for children.
- Discussed COVID-19 bivalent vaccines and vaccines for meningitis, polio, dengue, monkeypox and chikungunya vaccines.
- Discussed proposals regarding the vaccine schedule.
- Suggested the removal of egg allergies as a contraindication to vaccines made in eggs.
For Dr. Meryl Nass, an internist, biological warfare epidemiologist and member of the Children’s Health Defense (CHD) scientific advisory committee, last week’s proceedings lacked the due diligence needed to fully ascertain the safety of the vaccines and treatments being reviewed.
Nass told The Defender:
“The ACIP members — all M.D.s — and CDC staffers, all M.D.s or Ph.D.s or both, are a collection of very obedient adults who deliver what is expected but perform no due diligence on the materials or any actual regulatory processes.
“For this, they are well-rewarded.
“The monkeypox vaccine, which I am incredibly knowledgeable about because for 20 years, I have scoured unpublished FDA documents, company press releases and medical literature, almost certainly does not work and is dangerous. None of that was mentioned. And no one asks for such information.”
And writing on her blog, Nass stated:
“The mission of CDC and the ACIP members is to sign off on all possible vaccines as safe and effective, and to never turn over any stones that could reveal anything different. Then to roll all vaccines out to as broad a group of humans as humanly possible.”
ACIP says seniors ‘may’ get RSV vaccine, but overlooks other safety concerns
According to MedPage Today, ACIP recommended the new RSV vaccines for older adults on Wednesday “but opted not to give their strongest endorsement,” instead recommending “a talk with [a] medical provider first.”
STAT reported that ACIP recommended “anyone 60 and over should be able to get one of the new [RSV] vaccines … if they and their physicians think it would be worthwhile.”
According to STAT, ACIP was initially slated to vote on a broader recommendation that would have “urged all people 65 and older to get vaccinated” for RSV.
However, “that recommendation was watered down” after “several members of the committee expressed serious concerns about the decisions they were being asked to make based on the data the companies had provided.”
Reuters reported that while some committee members wanted to stick with the broader recommendation, “others had concerns that there was not enough data about how effective the vaccines are in people over the age of 75 and other high-risk groups.”
Two votes followed. In one, ACIP was asked whether “adults 65 years of age and older are recommended to receive a single dose of RSV vaccine.” The committee voted 9-5 to recommend that those age 65 and over “may” get an RSV vaccine after consultation with a doctor or pharmacist.
The other vote asked ACIP’s members whether “individual adults ages 60-64 may receive a single dose of RSV vaccine, using shared clinical decision-making” — that is, consultation with a doctor or pharmacist. Here, the result was 13-0 in favor, with one abstention.
ACIP’s recommendations are headed to the desk of outgoing CDC Director Rochelle Walensky, who is expected to sign off on them early this week. Her last day as head of the CDC is June 30. However, ACIP recommendations are not considered final until they are published in the Morbidity and Mortality Weekly Report.
The FDA recently approved the two vaccines — Pfizer’s Abrysvo and GSK’s Arexvy.
According to STAT, “It is expected both companies will provide vaccines to the market in time for the next RSV season.” However, the mild recommendations from ACIP “will likely lead to a lower uptake of the new vaccines than the manufacturers might have expected.”
Read More @ ChildrensHealthDefense.org
